ADCT
ADC Therapeutics SA
1.30$
-1.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 80.4% | 94.8% | 94.2% | 95.6% | 95.4% | 95.5% | 94.7% | 99.1% | 99.1% | 94.8% | 94.9% | 93.7% | |
| 66.5% | 78.5% | 76.1% | 80.7% | 78.6% | 77.9% | 71.4% | 82.3% | 81.0% | 80.9% | 79.2% | 78.4% | |
| 66.5% | 78.5% | 76.1% | 80.7% | 78.6% | 77.9% | 71.4% | 82.3% | 81.0% | 80.9% | 79.2% | 78.4% | |
| 4.5% | 7.1% | 7.5% | 6.2% | 6.9% | 6.3% | 11.7% | 8.1% | 7.9% | 9.0% | 10.7% | 10.0% | |
| 4.9% | 4.6% | 5.2% | 4.1% | 4.6% | 5.7% | 6.4% | 5.5% | 6.2% | 1.3% | 1.6% | 1.8% | |
| 3.3% | – | – | – | – | – | – | – | – | – | – | – | |
| 2.6% | – | – | – | – | – | – | – | – | – | – | – | |
| 111.6% | 141.8% | 163.1% | 135.4% | 149.3% | 162.9% | 187.4% | 161.9% | 182.2% | 157.5% | 174.2% | 181.7% | |
| 16.8% | 19.1% | 20.5% | 15.5% | 19.4% | 25.0% | 21.2% | 20.1% | 21.4% | 21.7% | 23.2% | 30.9% | |
| 3.4% | 0.4% | 0.5% | 0.4% | 0.4% | 0.4% | 0.5% | 0.6% | 0.3% | 0.9% | 1.6% | 2.2% | |
| 1.9% | 4.4% | 4.6% | 2.9% | 4.1% | 5.6% | 5.7% | 3.0% | 2.8% | 2.8% | 1.8% | 4.6% | |
| 20.9% | 31.8% | 36.8% | 30.6% | 32.7% | 35.3% | 41.8% | 35.6% | 39.8% | 34.8% | 38.1% | 39.5% | |
| -11.6% | -41.8% | -63.1% | -35.4% | -49.3% | -62.9% | -87.4% | -61.9% | -82.2% | -57.5% | -74.2% | -81.7% | |
| -264.5% | -376.4% | -448.8% | -381.6% | -419.0% | -463.8% | -562.1% | -494.0% | -562.4% | -506.2% | -572.5% | -603.3% | |
| 17.6% | 23.2% | 26.8% | 25.7% | 30.0% | 32.7% | 39.3% | 35.4% | 47.1% | 46.5% | 52.9% | 55.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.